We describe several mechanisms by which tumor-specific KRAS inhibition has direct and indirect effects on the TME, such as reduced expression of chemokines attracting immunosuppressive myeloid cells, enhanced uptake of tumor cells by antigen-presenting cells (APCs), and enhanced intrinsic and extrinsic interferon (IFN) responses. The gene discussed is IFNA1; the disease is neoplasm.